Trial · NCT03279731

Binge Eating Liraglutide Intervention

NCT03279731, Phase 3, Terminated, Kelly Allison; results first posted 2020-11-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Binge Eating Liraglutide Intervention. Trials, record NCT03279731. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03279731

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Binge Eating Liraglutide Intervention
NCT number: NCT03279731
Status: Terminated
Phases: Phase 3
Enrollment: 36 participants, actual
Lead sponsor: Kelly Allison
Conditions: Binge-Eating Disorder
Interventions: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml, Placebo
First posted: 2017-09-12
Last updated: 2020-11-24
Results first posted: 2020-11-24
Limitations and caveats: Error by Investigational Drug Service - randomization key interpreted incorrectly at n=21 n= 6 had 2+ consecutive boxes of same agent and were retained in analyses (data censored after first switch); 6 received same agent consistently; n=9 censored

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Binge Episodes	baseline and 17 weeks (or last observation carried forward)	Change in objective binge episodes per week from randomization (week 0) to study end (week 17)
Secondary	Remission From Binge-eating	13 to 17 weeks	the percentage of participants (completers) who have achieved remission from binge-eating (no binge episodes between weeks 13 - 17)
Secondary	Assessment of Improvement of Binge Eating Symptoms	week 17 (or last observation carried forward)	week 17 rating on the interviewer-based Clinical Global Impression of Improvement (CGII) Scale for global assessment of BED symptoms The CGII includes the following rating scale: Compared to the patient's condition at baseline to the project \[prior to medication initiation\], this patient's condition is: 1 very much improved; 2 much improved; 3 improved; 4 no change; 5 worse; 6 much worse; 7 very much worse.
Secondary	Change in Body Weight	baseline and 17 weeks (or last observation carried forward)	changes in body weight

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Binge Episodes	baseline and 17 weeks (or last observation carried forward)		objective binge episodes per week	MEAN
SECONDARY	Remission From Binge-eating	13 to 17 weeks	Remission was calculated for completers who had data from weeks 13-17	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Assessment of Improvement of Binge Eating Symptoms	week 17 (or last observation carried forward)		units on a scale	MEAN
SECONDARY	Change in Body Weight	baseline and 17 weeks (or last observation carried forward)	Last Observation Carried Forward	kg	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Binge Episodes	Liraglutide	-3.97	Standard Deviation 0.56	objective binge episodes per week
Binge Episodes	Placebo	-2.50	Standard Deviation .053	objective binge episodes per week
Remission From Binge-eating	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	3		Participants
Remission From Binge-eating	Placebo	4		Participants
Assessment of Improvement of Binge Eating Symptoms	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	1.52	Standard Deviation .27	units on a scale
Assessment of Improvement of Binge Eating Symptoms	Placebo	1.93	Standard Deviation .26	units on a scale
Change in Body Weight	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	-4.7	Standard Deviation 0.83	kg
Change in Body Weight	Placebo	-0.94	Standard Deviation 0.73	kg

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	19
Overall Study	STARTED	Placebo	17
Overall Study	COMPLETED	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	13
Overall Study	COMPLETED	Placebo	14
Overall Study	NOT COMPLETED	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	6
Overall Study	NOT COMPLETED	Placebo	3

Source ClinicalTrials.gov

Adverse events56

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	nausea	Gastrointestinal disorders	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	5	19	7
other	nausea	Gastrointestinal disorders	Placebo	3	17	3
other	diarrhea	Gastrointestinal disorders	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	5	19	5
other	diarrhea	Gastrointestinal disorders	Placebo	0	17	0
other	dry mouth	General disorders	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	3	19	3
other	dry mouth	General disorders	Placebo	0	17	0
other	upper respiratory infection	Infections and infestations	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	2	19	2
other	upper respiratory infection	Infections and infestations	Placebo	1	17	1
other	indigestion	Gastrointestinal disorders	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	2	19	2
other	indigestion	Gastrointestinal disorders	Placebo	2	17	2

1 to 10 of 56Source ClinicalTrials.gov

See all 56 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	0	19
Total, all-cause mortality	Placebo	0	17
Total, other adverse events	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	17	19
Total, other adverse events	Placebo	11	17
Total, serious adverse events	Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml	2	19
Total, serious adverse events	Placebo	1	17

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml vs Placebo: Remission From Binge-eating	Trial comparisons
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml vs Placebo: deaths from any cause	Trial comparisons
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03279731

GET https://conductscience.org/api/trials/v1/NCT03279731/events?page=2

API reference For AI assistants